Positive results from the Phase 2b trial evaluating delafloxacin (Rib-X Pharmaceuticauls) for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by methicillin- and quinolone-resistant Staphylococcus aureus (MRSA, QRSA) was presented today at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Delafloxacin was equally as efficacious in the treatment of ABSSSI as linezolid and vancomycin when compared using the objective endpoint of cessation of lesion spread and absence or resolution of fever in the 48–72 hour timeframe. The time-point to achieve maximal benefit for all three compounds was 72 hours.

When compared to linezolid and vancomycin using the objective endpoint of >20% or >30% reduction in lesion size in 48–72 hours, delafloxacin was shown to be numerically better and nearly statistically significant for >30%. Delafloxacin was shown to result in a greater percent reduction in the lesion size than either comparator by 72 hours.

For more information, visit www.rib-x.com.